4. Juni 2019Dr. Thomas Burtscher

ASCO 2019: TITAN und ENZAMET – zwei praxisverändernde Studien beim Prostatakarzinom

Dr. Thomas Burtscher, Universitätsklink für Urologie Innsbruck, berichtet über Apalutamid und Enzalutamid beim hormonsensitiven Prostatakarzinom, mögliche Kriterien zur Patientenselektion und inwieweit die BRCA-Testung in der urologischen Praxis angekommen ist.

Abstracts zum Video:

Abstract  5006
First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
Kim N. Chi

Abstract  LBA2
Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.
Christopher Sweeney

Abstract  5008
Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).
Michael J. Morris

Abstract  5005
TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.
Joaquin Mateo